Skip to main content

Checkpoint Capital L.P.

13F filer · CIK 0001977548
Reported Aug 14, 2026
Net buyer this quarter
13F portfolio value$390MU.S. long equity reported on 13F
Positions60 new · 2 closed
Net flow last quarter+$20.3MBuys minus sells
Top 10 positions weight100.0%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 20266 positions
RYTMRhythm Pharmaceuticals, Inc.$132M33.79%1.72%-3.4%Q4 2023
ARGXArgenx SE$122M31.25%0.21%-14.2%Q4 2023
RVMDRevolution Medicines, Inc.$76.9M19.72%0.19%+56.3%Q4 2024
CYTKCytokinetics Inc$40.5M10.38%0.38%+163.9%Q4 2023
IRONDisc Medicine, Inc.$17.6M4.51%0.63%-16.2%Q4 2023
TRVITrevi Therapeutics, Inc.$1.4M0.36%0.05%+50.0%Q4 2023
Q1 2026Reported May 15, 20268 positions
ARGXArgenx SE$112M40.10%0.25%+7.8%Q4 2023
RYTMRhythm Pharmaceuticals, Inc.$107M38.30%1.79%+23.7%Q4 2023
RVMDRevolution Medicines, Inc.$25.5M9.16%0.13%-29.0%Q4 2024
IRONDisc Medicine, Inc.$18.3M6.58%0.75%-36.7%Q4 2023
CYTKCytokinetics Inc$11.9M4.26%0.15%+7.9%Q4 2023
SEPNSepterna, Inc.$2.41M0.86%0.22%Not reportedQ1 2025
CRNXCrinetics Pharmaceuticals, Inc.$1.46M0.52%0.04%Not reportedQ3 2025
TRVITrevi Therapeutics, Inc.$597K0.21%0.04%Not reportedQ4 2023
Q4 2025Reported Feb 17, 20266 positions
ARGXArgenx SE$119M37.31%0.23%-5.3%Q4 2023
RYTMRhythm Pharmaceuticals, Inc.$106M33.18%1.48%+29.9%Q4 2023
IRONDisc Medicine, Inc.$36M11.24%1.20%+5.4%Q4 2023
RVMDRevolution Medicines, Inc.$29.5M9.21%0.19%-24.8%Q4 2024
CORTCorcept Therapeutics Inc$14M4.36%0.38%+2.3%Q1 2024
CYTKCytokinetics Inc$10.6M3.31%0.14%+343.8%Q4 2023
Q3 2025Reported Nov 14, 202510 positions
ARGXArgenx SE$111M37.07%0.25%0.0%Q4 2023
RYTMRhythm Pharmaceuticals, Inc.$77.1M25.84%1.15%-28.0%Q4 2023
CORTCorcept Therapeutics Inc$32.6M10.92%0.37%+14.1%Q1 2024
IRONDisc Medicine, Inc.$28.4M9.52%1.23%+62.3%Q4 2023
RVMDRevolution Medicines, Inc.$23M7.70%0.26%+75.8%Q4 2024
CRNXCrinetics Pharmaceuticals, Inc.$10.8M3.63%0.28%NewQ3 2025
SEPNSepterna, Inc.$5.33M1.78%0.63%-51.7%Q1 2025
STOKStoke Therapeutics, Inc.$4.98M1.67%0.38%Not reportedQ3 2024
KYMRKymera Therapeutics, Inc.$3.5M1.17%0.09%-42.3%Q2 2024
CYTKCytokinetics Inc$2.07M0.69%0.03%Not reportedQ4 2023
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.